[HTML] nih.gov

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

G Zhang, MA Park, C Mitchell, H Hamed… - Clinical cancer …, 2008 - AACR
Abstract Purpose and Design: Mechanism (s) by which the multikinase inhibitor sorafenib
and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal, and pancreatic …
被引用次数：128 相关文章 所有 9 个版本
[PDF] tandfonline.com

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

MA Park, G Zhang, AP Martin, H Hamed… - Cancer biology & …, 2008 - Taylor & Francis
We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion
to kill carcinoma cells by activating CD95, and this drug combination is entering phase I …
被引用次数：203 相关文章 所有 12 个版本
[HTML] nih.gov

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and-independent mechanisms

T Walker, C Mitchell, MA Park, A Yacoub, M Graf… - Molecular …, 2009 - ASPET
We examined the interaction between the multikinase inhibitor sorafenib and histone
deacetylase inhibitors. Sorafenib and vorinostat synergized (sorafenib+ vorinostat) to kill …
被引用次数：109 相关文章 所有 12 个版本
[HTML] nih.gov

Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells

MA Park, R Reinehr, D Häussinger… - Molecular cancer …, 2010 - AACR
Sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating
CD95; the present studies have determined how sorafenib and vorinostat individually …
被引用次数：89 相关文章 所有 9 个版本
[HTML] nih.gov

Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent …

MA Park, C Mitchell, G Zhang, A Yacoub, J Allegood… - Cancer research, 2010 - AACR
The targeted therapeutics sorafenib and vorinostat interact in a synergistic fashion to kill
carcinoma cells by activating CD95, and this drug combination is entering phase I …
被引用次数：111 相关文章 所有 10 个版本
[PDF] spandidos-publications.com

Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition

LW Rong, RX Wang, XL Zheng… - Oncology …, 2017 - spandidos-publications.com
The small molecule multi-kinase inhibitor sorafenib has become the standard systemic
treatment for patients with advanced hepatocellular carcinoma (HCC) and renal cell …
被引用次数：41 相关文章 所有 10 个版本
[HTML] nih.gov

BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing

AP Martin, MA Park, C Mitchell, T Walker… - Molecular …, 2009 - ASPET
We examined whether the multikinase inhibitor sorafenib and histone deacetylase inhibitors
(HDACI) interact to kill pancreatic carcinoma cells and determined the impact of inhibiting …
被引用次数：101 相关文章 所有 11 个版本
[PDF] spandidos-publications.com

Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling

FT Hsu, YC Liu, IT Chiang, RS Liu… - International …, 2014 - spandidos-publications.com
Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and
particularly for those who are unsuitable to receive life-prolonging transarterial …
被引用次数：63 相关文章 所有 15 个版本

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms

D Llobet, N Eritja, A Yeramian, J Pallares… - European Journal of …, 2010 - Elsevier
Sorafenib induces apoptosis and enhances Tumour Necrosis Factor-Related Apoptosis-
Inducing Ligand (TRAIL)-induced cell killing of tumoural cells. We have investigated the …
被引用次数：60 相关文章 所有 7 个版本
[PDF] researchgate.net

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2 …

C Yu, BB Friday, JP Lai, L Yang, J Sarkaria… - Molecular cancer …, 2006 - AACR
This study was undertaken to characterize preclinical cytotoxic interactions for human
malignancies between the multikinase inhibitor sorafenib (BAY 43-9006) and proteasome …
被引用次数：126 相关文章 所有 7 个版本